Vivace® Direct – April 23rd, 2024

In the ever-evolving landscape of aesthetic medicine, advancements that prioritize patient safety while delivering optimal results are paramount. One such breakthrough is the Vivace Ultra™, a revolutionary device that has recently participated in the ASCA (Accreditation Scheme for Conformity Assessment) seal by the FDA. Coupled with its industry-first ultrasound mapping technology, Vivace Ultra™ stands out as a game-changer in the field, ensuring heightened safety for both providers and patients.

The Significance of the ASCA Seal

The ASCA seal from the FDA holds immense significance within the aesthetic medicine community. It signifies that a device has met rigorous standards set forth by regulatory authorities, ensuring its safety and efficacy. Vivace Ultra™’s attainment of this prestigious seal underscores its commitment to upholding the highest standards of quality and safety.  It is the only RF Microneedling device to have this seal.

Understanding Vivace Ultra™’s Ultrasound Mapping Technology

What sets Vivace Ultra™ apart is its utilization of linear-array ultrasound mapping technology, a first in the industry. This technology allows providers to precisely visualize the layers of the skin, in real-time. By offering a comprehensive view of the treatment area, providers can navigate with unparalleled accuracy, minimizing the risk of complications.

Enhancing Provider Safety

For aesthetic providers, safety is non-negotiable. Vivace Ultra™’s ultrasound mapping technology empowers practitioners to perform procedures with enhanced confidence and precision. By accurately assessing the patient’s anatomy before and during treatment, providers can tailor their approach to each individual, mitigating potential risks and ensuring optimal outcomes.

Elevating Patient Safety and Satisfaction

Patients seeking aesthetic procedures prioritize safety alongside their desired results. With Vivace Ultra™, they can rest assured knowing that their provider is equipped with state-of-the-art technology designed to prioritize their safety at every step of the process. By leveraging ultrasound mapping, providers can customize treatments to each patient’s unique anatomy, minimizing the risk of adverse events and maximizing satisfaction.

Conclusion

In the realm of aesthetic medicine, safety should always remain paramount. With the FDA’s ASCA seal and industry-first ultrasound mapping technology, Vivace Ultra™ sets a new standard for safety and efficacy in aesthetic procedures. By investing in innovative technologies like Vivace Ultra™, both providers and patients can embark on their aesthetic journeys with confidence, knowing that their safety and satisfaction are in capable hands.